Welcome to the THALOMID REMS program

Important information about THALOMID and the THALOMID Risk Evaluation and Mitigation Strategy (REMS) program

  • THALOMID® (thalidomide) is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with THALOMID provided adequate precautions are taken to avoid pregnancy
  • To avoid embryo-fetal exposure, THALOMID is only available under a restricted distribution program called “THALOMID REMS”
  • Only prescribers and pharmacies certified by the THALOMID REMS program can prescribe and dispense THALOMID to patients who are enrolled and meet all the conditions of the THALOMID REMS program

The goals of the THALOMID risk evaluation and mitigation strategy are as follows:

  1. To prevent the risk of embryo-fetal exposure to THALOMID
  2. To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions for THALOMID

For additional information about the THALOMID REMS program, please contact the REMS Call Center at 1-888-423-5436

THALOMID and THALOMID REMS are registered trademarks of Celgene Corporation, a Bristol-Myers Squibb Company.